Clinical Trials in Romania

• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended
  2023-506696-10-00 Phase III Non-Small Cell Lung Cancer F. Hoffmann-La Roche AG
• RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHAR… Ended
  2023-510247-38-00 Phase I (Other) Rheumatoid arthritis Ilab Co. Ltd.
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 Phase II/III The participants must have a histologically confirmed diagno… Merck Sharp & Dohme LLC
• Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic… Ended
  2022-503009-39-00 Phase I (Other) Subacute Cutaneous Lupus Erythematosus Bristol-Myers Squibb Services Unlimited Company
• A Single Dose, Two – stage, Fasting State, Bioequivalence Study of Rifaximin 200 mg, film-coated tablets (Antibiotice S.A.) vs. Normix® 200 … Ended
  2024-510671-38-00 healthy subjects Antibiotice S.A.
• A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-… Ended
  2023-506881-30-00 Phase I (Other) Melanoma H e x a l AG
• A study to investigate the safety, tolerability, and pharmacokinetics of Ent001 in patients with moderately to severely active ulcerative co… Ended
  2023-507340-36-00 Phase I (Other) Inflammatory bowel disease (moderate to severe active ulcera… Enthera S.r.l.
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 Phase III Uncontrolled and Resistant Hypertension Mineralys Therapeutics Inc.
• Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended
  2022-501969-42-00 Phase III Intermediate-stage hepatocellular carcinoma with beyond up-t… Translational Research In Oncology
• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 Phase III complicated urinary tract infection (cUTI) or acute pyelonep… Spero Therapeutics Inc.
• Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended
  2023-508177-85-00 Phase III Healthy volunteers (Meningococcal infection) Sanofi Pasteur
• A Single Dose, Fed state, Crossover Replicate, Bioequivalence Study of Naproxen 500 mg/ Esomeprazole 20 mg modified-release tablets (Antibio… Ended
  2023-508621-27-00 healthy subjects Antibiotice S.A.
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With… Ended
  2023-507280-18-00 Phase III Type 2 Diabetes Eli Lilly & Co.
• An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaft… Ended
  2023-508115-23-00 Cystic Fibrosis Sun Pharmaceutical Industries Limited
• A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liv… Ended
  2023-506083-13-00 Phase II clinically significant portal hypertension (CSPH) in decompe… Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TAB… Ended
  2023-506596-10-00 Study performed on healthy volunteers. neuraxpharm Arzneimittel GmbH
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended
  2023-503333-22-00 Phase III Moderate to severe controlled asthma according to Step 4 and… Chiesi Farmaceutici S.p.A.
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 Phase III Pulmonary Arterial Hypertension GB002 Inc.
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 Phase II Ulcerative Colitis Janssen - Cilag International
• A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended
  2022-502716-37-00 Phase II Recurrent or advanced/metastatic solid tumors who are immuno… Incyte Corp.
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 Phase II Asthma Chiesi Farmaceutici S.p.A.
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 Phase III Acute Coronary Syndrome Janssen - Cilag International
• An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Dapagli… Ended
  2023-506408-18-00 diabetes Sun Pharmaceutical Industries Limited
• A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended
  2022-502778-18-00 Phase III ulcerative colitis Polpharma Biologics S.A.

Showing 697–720 of 865 trials